Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a)

被引:66
作者
Arem, R
Escalante, DA
Arem, N
Morrisett, JD
Patsch, W
机构
[1] BAYLOR COLL MED, DEPT MED, DIV ENDOCRINOL & METAB, HOUSTON, TX 77030 USA
[2] BAYLOR COLL MED, DEPT MED, DIV ATHEROSCLEROSIS, HOUSTON, TX 77030 USA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1995年 / 44卷 / 12期
关键词
D O I
10.1016/0026-0495(95)90075-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of L-thyroxine therapy on lipoprotein fractions was assessed in 15 patients with overt hypothyroidism (14 women and one man aged 45 +/- 3.9 years; thyrotropin [TSH]: mean +/- SEM, 42 +/- 6.5 mlU/L; range, 20.5 to 106.5) and 14 patients with subclinical hypothyroidism (13 women and one man aged 41 +/- 4 years; TSH: mean +/- SEM, 9.1 +/- 1 mlU/L; range, 5.1 to 17.3), Easting serum lipid levels were measured initially and 4 months after achievement of a euthyroid state with incremental L-thyroxine therapy (TSH: mean +/- SEM, 1.8 +/- 0.4 mlU/L: range, 0.3 to 4.9 for both groups). In the overtly hypothyroid group, restoration of a euthyroid state was associated with a significant reduction in total cholesterol, and apo B. In the subclinically hypothyroid group, there was a significant reduction of only total cholesterol (199.6 +/- 13.2 v 183.4 +/- 11.6 mg/dL) and LDL-C (131.6 +/- 8.4 v 114 +/- 9.25 mg/dL). In contrast, lipoprotein(a) [Lp(a)] was unaffected by the incremental adjustment of L-thyroxine therapy in both groups (overt, 34.3 +/- 8.8 v 35.6 +/- 6.7 mg/dL; subclinical, 23.0 +/- 8.6 v 29.4 +/- 9.5 mg/dL). We conclude that restoration of a euthyroid state in patients with overt hypothyroidism has no significant effect on Lp(a) levels, and confirm that subclinical hypothyroidism is associated with a significant increase in LDL C. known to have an atherogenic effect. Copyright (C) 1995 by W.B. Saunders Company
引用
收藏
页码:1559 / 1563
页数:5
相关论文
共 39 条
  • [1] LDL/HDL-CHANGES IN SUBCLINICAL HYPOTHYROIDISM - POSSIBLE RISK-FACTORS FOR CORONARY HEART-DISEASE
    ALTHAUS, BU
    STAUB, JJ
    RYFFDELECHE, A
    OBERHANSLI, A
    STAHELIN, HB
    [J]. CLINICAL ENDOCRINOLOGY, 1988, 28 (02) : 157 - 163
  • [2] LIPOPROTEIN AND APOLIPOPROTEIN LEVELS IN SUBCLINICAL HYPOTHYROIDISM - EFFECT OF LEVOTHYROXINE THERAPY
    AREM, R
    PATSCH, W
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (10) : 2097 - 2100
  • [3] COMPOSITION OF LOW-DENSITY LIPOPROTEIN AND VERY-LOW-DENSITY LIPOPROTEIN SUBFRACTIONS IN PRIMARY HYPO-THYROIDISM AND THE EFFECT OF HORMONE-REPLACEMENT THERAPY
    BALLANTYNE, FC
    EPENETOS, AA
    CASLAKE, M
    FORSYTHE, S
    BALLANTYNE, D
    [J]. CLINICAL SCIENCE, 1979, 57 (01) : 83 - 88
  • [4] BERG K, 1979, CLIN GENET, V16, P347
  • [5] THE RELATION OF LIPOPROTEIN[A] CONCENTRATIONS AND APOLIPOPROTEIN[A] PHENOTYPES WITH ASYMPTOMATIC ATHEROSCLEROSIS IN SUBJECTS OF THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY
    BROWN, SA
    MORRISETT, JD
    BOERWINKLE, E
    HUTCHINSON, R
    PATSCH, W
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (11): : 1558 - 1566
  • [6] DECREASED HDL CHOLESTEROL IN SUBCLINICAL HYPOTHYROIDISM - THE EFFECT OF L-THYROXINE THERAPY
    CARON, P
    CALAZEL, C
    PARRA, HJ
    HOFF, M
    LOUVET, JP
    [J]. CLINICAL ENDOCRINOLOGY, 1990, 33 (04) : 519 - 523
  • [7] REGULATORY ROLE OF TRIIODOTHYRONINE IN THE DEGRADATION OF LOW-DENSITY LIPOPROTEIN BY CULTURED HUMAN-SKIN FIBROBLASTS
    CHAIT, A
    BIERMAN, EL
    ALBERS, JJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1979, 48 (05) : 887 - 889
  • [8] DAHLEN G, 1975, CLIN GENET, V7, P334
  • [9] Dahlen G H, 1988, Prog Clin Biol Res, V255, P27
  • [10] ASSOCIATION OF LEVELS OF LIPOPROTEIN LP(A), PLASMA-LIPIDS, AND OTHER LIPOPROTEINS WITH CORONARY-ARTERY DISEASE DOCUMENTED BY ANGIOGRAPHY
    DAHLEN, GH
    GUYTON, JR
    ATTAR, M
    FARMER, JA
    KAUTZ, JA
    GOTTO, AM
    [J]. CIRCULATION, 1986, 74 (04) : 758 - 765